Literature DB >> 26295295

Nesfatin-1 and Vitamin D levels may be associated with systolic and diastolic blood pressure values and hearth rate in polycystic ovary syndrome.

Figen Kir Sahin1, Serap Baydur Sahin, Ulku Mete Ural, Medine Cumhur Cure, Senol Senturk, Yesim Bayoglu Tekin, Gulsah Balik, Erkan Cure, Suleyman Yuce, Aynur Kirbas.   

Abstract

Obesity, insulin resistance (IR), inflammation, and hyperandrogenism may lead to polycystic ovary syndrome (PCOS) and hypertension. Nesfatin-1 (N1) may be related to IR, obesity, and hypertension. Furthermore, a vitamin D (VD) deficiency is associated with hypertension and PCOS. We aimed to investigate N1 and VD levels in PCOS that have an effect on systolic and diastolic blood pressure (BP) and heart rate (HR).This study included 54 patients with PCOS and 48 age-body mass index (BMI)-matched healthy controls. PCOS was diagnosed according to clinical practice guidelines. Ferriman-Gallwey scores (FGS) were calculated, while N1, VD, and other hormonal and biochemical parameters were measured for all subjects. Systolic and diastolic BP was measured as well. HR was calculated using an electrocardiogram.The levels of N1 (p < 0.001), high-sensitivity C-reactive protein (hs-CRP) (p = 0.036), homeostasis model assessment as an index of insulin resistance (HOMA-IR) (p < 0.001), systolic (p < 0.001) and diastolic (p < 0.001) BP and HR (p < 0.001) in the PCOS group were significantly higher than in the control group. However, the VD levels of the PCOS group were lower than the control group (p = 0.004). N1 had a strong positive correlation with BMI, HOMA-IR, hs-CRP, luteinizing hormone, systolic and diastolic BP, and HR. VD levels were negatively correlated with HOMA-IR and luteinizing hormone.Elevated N1 and decreased VD levels may be related to the presence of high-normal BP or hypertension in PCOS subjects.  N1 level may be associated with an increased BP due to its relation to inflammation and IR.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26295295      PMCID: PMC4594327          DOI: 10.17305/bjbms.2015.432

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  38 in total

1.  The anorexigenic and hypertensive effects of nesfatin-1 are reversed by pretreatment with an oxytocin receptor antagonist.

Authors:  Gina L C Yosten; Willis K Samson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-03-24       Impact factor: 3.619

2.  Nesfatin-1 exerts long-term effect on food intake and body temperature.

Authors:  K Könczöl; O Pintér; S Ferenczi; J Varga; K Kovács; M Palkovits; D Zelena; Z E Tóth
Journal:  Int J Obes (Lond)       Date:  2012-01-31       Impact factor: 5.095

3.  Nesfatin-1 correlates with hypertension in overweight or obese Han Chinese population.

Authors:  Yanyan Zhao; Xiaojun Ma; Qingzhu Wang; Yingni Zhou; Yuanyuan Zhang; Lina Wu; Hongfei Ji; Guijun Qin; Jieli Lu; Yufang Bi; Guang Ning
Journal:  Clin Exp Hypertens       Date:  2014-03-28       Impact factor: 1.749

4.  The evaluation of Nesfatin-1 levels in patients with OSAS associated with metabolic syndrome.

Authors:  O Aksu; B Aydın; D K Doguç; I Ilhan; O Ozturk; A Altuntas; H Demirkan; B K Koroglu; M N Tamer
Journal:  J Endocrinol Invest       Date:  2014-11-29       Impact factor: 4.256

5.  Investigation of the relationship between vitamin D and bone mineral density in newly diagnosed multiple sclerosis.

Authors:  Aynur Kirbas; Serkan Kirbas; Omer Anlar; Aysegul Kucukali Turkyilmaz; Medine Cumhur Cure; Hasan Efe
Journal:  Acta Neurol Belg       Date:  2012-08-16       Impact factor: 2.396

6.  Identification of nesfatin-1 as a satiety molecule in the hypothalamus.

Authors:  Shinsuke Oh-I; Hiroyuki Shimizu; Tetsurou Satoh; Shuichi Okada; Sachika Adachi; Kinji Inoue; Hiroshi Eguchi; Masanori Yamamoto; Toshihiro Imaki; Koushi Hashimoto; Takafumi Tsuchiya; Tsuyoshi Monden; Kazuhiko Horiguchi; Masanobu Yamada; Masatomo Mori
Journal:  Nature       Date:  2006-10-01       Impact factor: 49.962

7.  Does low pentraxin-3 levels associate with polycystic ovary syndrome and obesity?

Authors:  Figen Kir Sahin; Serap Baydur Sahin; Gulsah Balik; Ulku Mete Ural; Yesim Bayoglu Tekin; Medine Cumhur Cure; Senol Senturk; Suleyman Yuce; Erkan Cure
Journal:  Int J Clin Exp Med       Date:  2014-10-15

Review 8.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

9.  The relation of serum nesfatin-1 level with metabolic and clinical parameters in obese and healthy children.

Authors:  Ayhan Abaci; Gonul Catli; Ahmet Anik; Tuncay Kume; Ece Bober
Journal:  Pediatr Diabetes       Date:  2013-01-24       Impact factor: 4.866

10.  Nesfatin-1 in human and murine cardiomyocytes: synthesis, secretion, and mobilization of GLUT-4.

Authors:  Sandra Feijóo-Bandín; Diego Rodríguez-Penas; Vanessa García-Rúa; Ana Mosquera-Leal; Manuel Francisco Otero; Eva Pereira; José Rubio; Isabel Martínez; Luisa María Seoane; Oreste Gualillo; Manuel Calaza; Tomás García-Caballero; Manuel Portolés; Esther Roselló-Lletí; Carlos Diéguez; Miguel Rivera; José Ramón González-Juanatey; Francisca Lago
Journal:  Endocrinology       Date:  2013-09-24       Impact factor: 4.736

View more
  12 in total

1.  Increased blood pressure in nesfatin/nuclebindin-2-transgenic mice.

Authors:  Yusaku Mori; Hiroyuki Shimizu; Hideki Kushima; Munenori Hiromura; Michishige Terasaki; Michitaka Tanaka; Aya Osaki; Tsutomu Hirano
Journal:  Hypertens Res       Date:  2017-04-27       Impact factor: 3.872

Review 2.  Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome.

Authors:  Tuba Tekin; Betul Cicek; Nurefsan Konyaligil
Journal:  Eurasian J Med       Date:  2019-08-19

Review 3.  Cardiometabolic Features of Polycystic Ovary Syndrome: Role of Androgens.

Authors:  Licy L Yanes Cardozo; Damian G Romero; Jane F Reckelhoff
Journal:  Physiology (Bethesda)       Date:  2017-09

Review 4.  Nesfatin-1: a new energy-regulating peptide with pleiotropic functions. Implications at cardiovascular level.

Authors:  Sandra Feijóo-Bandín; Diego Rodríguez-Penas; Vanessa García-Rúa; Ana Mosquera-Leal; José Ramón González-Juanatey; Francisca Lago
Journal:  Endocrine       Date:  2015-12-12       Impact factor: 3.633

5.  Can Nesfatin-1 Predict Hypertension in Obese Children?

Authors:  Hatice Güneş; Filiz Alkan Baylan; Hakan Güneş; Fatih Temiz
Journal:  J Clin Res Pediatr Endocrinol       Date:  2019-07-24

6.  Efficacy of Vitamin D Combined with Metformin and Clomiphene in the Treatment of Patients with Polycystic Ovary Syndrome Combined with Infertility.

Authors:  Lili Zhuang; Wei Cui; Jianxiang Cong; Yinghong Zhang
Journal:  Iran J Public Health       Date:  2019-10       Impact factor: 1.429

7.  Neutrophil/Lymphocyte Ratio, Serum Endocan, and Nesfatin-1 Levels in Patients with Psoriasis Vulgaris Undergoing Phototherapy Treatment.

Authors:  Aybala Erek Toprak; Emin Ozlu; Tugba Kevser Uzuncakmak; Emre Yalcınkaya; Sadık Sogut; Ayşe Serap Karadag
Journal:  Med Sci Monit       Date:  2016-04-12

8.  The effects of Desflurane and Sevoflurane on Nesfatin-1 levels in laparoscopic Cholecystectomy: a randomized controlled trial.

Authors:  A T D Ozcan; C B Altin; S Erdogan; M Ergin; A Çiftçi; H Kara; S M Aksoy; A But
Journal:  BMC Anesthesiol       Date:  2018-02-16       Impact factor: 2.217

Review 9.  Current Understanding of the Role of Nesfatin-1.

Authors:  Martha A Schalla; Andreas Stengel
Journal:  J Endocr Soc       Date:  2018-09-10

10.  Plasma nesfatin-1 and DDP-4 levels in patients with coronary artery disease: Kozani study.

Authors:  Nikolaos P E Kadoglou; Emmanouil Korakas; Stylianos Lampropoulos; Eirini Maratou; George Kassimis; Nikolaos Patsourakos; Panagiotis Plotas; Paraskevi Moutsatsou; Vaia Lambadiari
Journal:  Cardiovasc Diabetol       Date:  2021-08-13       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.